

**IN THE CLAIMS**

Please amend the claims as shown in the following detailed claim listing. The detailed claim listing is intended to reflect cancellation of claims 2 and 10-34; and the amendment of previously pending claim 1. The specific amendments to individual claims are detailed in the following detailed claim listing.

1. (Currently Amended) A purified mammalian dihydroouabain-like factor (Dh-OLF) having binding reactivity with antibody raised against ~~plant-related~~ dihydroouabain (dho).
2. (Cancelled) The factor of claim 1 having the same high pressure liquid chromatography elution pattern as dho-B.
3. (Previously Presented) The factor of claim 1 having less than about 2-3% binding reactivity with the antibody raised to plant-derived ouabain or mammalian ouabain-like sodium pump inhibitory factor (OLF).
4. (Original) The factor of claim 1 having 10-fold lower potency than OLF and 3-fold higher potency than dho for inhibiting sodium pump activity.
5. (Original) The factor of claim 1 which is of human origin.
6. (Original) The factor of claim 1 which is of bovine origin.
7. (Original) The factor of claim 1 which is obtained by reduction of OLF.
8. (Original) A pharmaceutical composition comprising the mammalian Dh-OLF factor of claim 1 and a pharmaceutically or veterinarily acceptable carrier.

**AMENDMENT & RESPONSE UNDER 37 C.F.R. § 1.116**

Serial Number: 09/503559

**Page 3**

Dkt: 1160.003US1

Filing Date: February 11, 2000

Title: DIHYDROOUABAIN-LIKE FACTOR AND DIAGNOSTIC & THERAPEUTIC COMPOSITIONS AND METHODS

9. (Original) The composition of claim 8 in the form of a formulation selected from the group consisting of oral, parenteral, ophthalmic, slow release and enteric coating formulations.

10-34 (Cancelled)